Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
- 7 December 2018
- journal article
- review article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (2) , 603-608
Abstract
Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS.Keywords
This publication has 15 references indexed in Scilit:
- Marked hyperferritinemia does not predict for HLH in the adult populationBlood, 2015
- Possible macrophage activation syndrome following initiation of adalimumab in a patient with adult-onset still’s diseasePan African Medical Journal, 2014
- Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis.2010
- Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumabJoint Bone Spine, 2010
- A rare trigger for macrophage activation syndromeRheumatology International, 2009
- Macrophage Activation Syndrome Associated with Etanercept in a Child with Systemic Onset juvenile Idiopathic Arthritis2009
- Ankylosing spondylitis presenting with macrophage activation syndromeClinical Rheumatology, 2007
- Macrophage activation syndrome after etanercept treatment.2007
- Syndrome d’activation macrophagique après traitement par infliximab pour maladie de Crohn fistuliséeLa Presse Médicale, 2005
- Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.2003